You May Also Like...
NBCC made the case in 2008 that accelerated approval for bevacizumab (Avastin®) was lowering the bar on drug approval. There
Read MorePersonalizing Mammography by Breast Density and Other Risk Factors July 5, 2011 The results of an analysis estimating the cost-effectiveness of mammography by age,
Read More